Catalyst
Slingshot members are tracking this event:
PDUFA Date of April 2017 for Pfizer's (PFE) Supplemental New Drug Application (sNDA) for Ibrance/Letrozole in Postmenopausal Women with Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| PFE |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Apr 03, 2017
Occurred Source:
http://www.pfizer.com/news/press-release/press-release-detail/ibrance_palbociclib_receives_fda_regular_approval_and_expanded_indication_for_first_line_hr_her2_metastatic_breast_cancer
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Supplemental New Drug Application, Snda, Ibrance, Letrozole, Postmenopausal Women, Estrogen Receptor Positive, Human Epidermal Growth Factor Receptor 2, Metastatic Breast Cancer, Er+, Her2-
